Xiangxue Pharmaceutical (300147) - Total Assets
Based on the latest financial reports, Xiangxue Pharmaceutical (300147) holds total assets worth CN¥6.66 Billion CNY (≈ $975.13 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Xiangxue Pharmaceutical (300147) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Xiangxue Pharmaceutical - Total Assets Trend (2007–2025)
This chart illustrates how Xiangxue Pharmaceutical's total assets have evolved over time, based on quarterly financial data. Explore Xiangxue Pharmaceutical long-term investment allocation to see how much of total assets are deployed in long-term investments.
Xiangxue Pharmaceutical - Asset Composition Analysis
Current Asset Composition (December 2025)
Xiangxue Pharmaceutical's total assets of CN¥6.66 Billion consist of 23.8% current assets and 76.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 3.8% |
| Accounts Receivable | CN¥750.42 Million | 11.1% |
| Inventory | CN¥295.43 Million | 4.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥979.34 Million | 14.5% |
| Goodwill | CN¥199.72 Million | 3.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Xiangxue Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Xiangxue Pharmaceutical market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Xiangxue Pharmaceutical's current assets represent 23.8% of total assets in 2025, an increase from 18.3% in 2007.
- Cash Position: Cash and equivalents constituted 3.8% of total assets in 2025, down from 8.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 8.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 14.5% of total assets.
Xiangxue Pharmaceutical Competitors by Total Assets
Key competitors of Xiangxue Pharmaceutical based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Xiangxue Pharmaceutical - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.24 | 0.28 | 0.44 |
| Quick Ratio | 0.19 | 0.22 | 0.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-5.01 Billion | CN¥-4.18 Billion | CN¥-3.38 Billion |
Xiangxue Pharmaceutical - Advanced Valuation Insights
This section examines the relationship between Xiangxue Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.57 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -10.0% |
| Total Assets | CN¥6.75 Billion |
| Market Capitalization | $878.63 Million USD |
Valuation Analysis
Below Book Valuation: The market values Xiangxue Pharmaceutical's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Xiangxue Pharmaceutical's assets decreased by 10.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Xiangxue Pharmaceutical (2007–2025)
The table below shows the annual total assets of Xiangxue Pharmaceutical from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.75 Billion ≈ $987.02 Million |
-10.05% |
| 2024-12-31 | CN¥7.50 Billion ≈ $1.10 Billion |
-9.45% |
| 2023-12-31 | CN¥8.28 Billion ≈ $1.21 Billion |
-11.47% |
| 2022-12-31 | CN¥9.35 Billion ≈ $1.37 Billion |
-17.82% |
| 2021-12-31 | CN¥11.38 Billion ≈ $1.67 Billion |
+16.39% |
| 2020-12-31 | CN¥9.78 Billion ≈ $1.43 Billion |
+15.56% |
| 2019-12-31 | CN¥8.46 Billion ≈ $1.24 Billion |
-1.90% |
| 2018-12-31 | CN¥8.63 Billion ≈ $1.26 Billion |
-8.63% |
| 2017-12-31 | CN¥9.44 Billion ≈ $1.38 Billion |
+18.18% |
| 2016-12-31 | CN¥7.99 Billion ≈ $1.17 Billion |
+71.73% |
| 2015-12-31 | CN¥4.65 Billion ≈ $680.73 Million |
+29.64% |
| 2014-12-31 | CN¥3.59 Billion ≈ $525.08 Million |
+3.27% |
| 2013-12-31 | CN¥3.47 Billion ≈ $508.46 Million |
+17.83% |
| 2012-12-31 | CN¥2.95 Billion ≈ $431.54 Million |
+53.50% |
| 2011-12-31 | CN¥1.92 Billion ≈ $281.12 Million |
+4.03% |
| 2010-12-31 | CN¥1.85 Billion ≈ $270.22 Million |
+164.44% |
| 2009-12-31 | CN¥698.31 Million ≈ $102.19 Million |
+26.63% |
| 2008-12-31 | CN¥551.47 Million ≈ $80.70 Million |
-0.35% |
| 2007-12-31 | CN¥553.43 Million ≈ $80.98 Million |
-- |
About Xiangxue Pharmaceutical
Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, diet s… Read more